Welcome!

News Feed Item

Brain Cancer Researcher Eric Holland, One Of The World's Top Neurosurgeons, To Join Fred Hutch And UW Medicine

He is recruited to establish a preeminent brain cancer program in Seattle

SEATTLE, April 1, 2013 /PRNewswire/ -- Eric Holland, M.D., Ph.D., an internationally renowned neurosurgeon and brain cancer researcher, has been recruited from Memorial Sloan-Kettering Cancer Center to Fred Hutchinson Cancer Research Center and the University of Washington to establish world-class research programs on brain and other solid-tumor cancers in Seattle. He will arrive this summer.

At Fred Hutch, where Holland's research laboratory will be based, he will be senior vice president and director of the Human Biology Division, an interdisciplinary program that encourages collaboration among faculty with a broad range of expertise – from molecular and cellular biology to genetics and clinical research. This unique structure fosters laboratory-based, computational and clinical research that yields discoveries which can be rapidly translated into treatments for cancer patients.

He will replace Denise Galloway, Ph.D., interim director and member of the Human Biology Division, who assumed that role in May 2011 upon the retirement of former division Director Barbara Trask, Ph.D.

"As a practicing neurosurgeon with an outstanding track record in molecular biology and genetics, Eric is at the forefront of translating laboratory advances into advanced molecular therapeutics – expertise that will be instrumental in catalyzing our efforts to build strength in clinical molecular diagnostics and precision oncology," said Larry Corey, M.D., president and director of Fred Hutch. "I am confident that Eric will help us apply the strategies he has developed and used so successfully for brain tumors to many other types of solid-tumor cancers. His recruitment will catalyze numerous opportunities of this kind for our institutions," he said.

With advances in genomics increasingly playing an important role in solid-tumor oncology, Holland's expertise will provide strong leadership in this area, strengthening Seattle's reputation in translational, solid-tumor research.

At Fred Hutch, Holland will oversee the recruitment of new laboratory-based investigators who are at the forefront of solid-tumor translational research in areas such as breast, prostate, gastrointestinal and other cancers.

At UW Medicine, Holland will be a professor of neurological surgery, hold the Chap and Eve Alvord and Elias Alvord Chair in Neuro-oncology and will direct the Nancy and Buster Alvord Brain Tumor Center. The Alvord Center was established in 2009 to promote, develop and coordinate outstanding interdisciplinary brain tumor care and research among physicians and scientists in a variety of fields ranging from neurology to radiation oncology.

As director of the Alvord Brain Tumor Center, one of Holland's first priorities will be to recruit a team of internationally renowned brain cancer investigators to implement the vision of the late Ellsworth "Buster" Alvord, a Seattle philanthropist and former head of the UW Department of Neuropathology. Alvord and his family funded five endowed chairs in five different UW Medicine departments to create a multidisciplinary research center to focus on brain cancer.

"Eric Holland is exceptionally well qualified to lead the Alvord Brain Tumor Center, and I am confident that he will recruit outstanding researchers and clinicians to establish the Alvord Center as the best in the world," said Paul G. Ramsey, M.D., CEO of UW Medicine and dean of the UW School of Medicine. "Under Dr. Holland's leadership, we will be able to fulfill the vision for brain cancer research and clinical care established by Buster Alvord when he and his family made their extraordinarily generous commitment to establish the Alvord Center. I am delighted to welcome Eric Holland to UW Medicine."

Holland said he is looking forward to the challenge of developing a world-class brain cancer and solid-tumor program in Seattle to build on the Hutchinson Center's pioneering, Nobel Prize-winning work in bone-marrow transplantation to treat leukemia and other blood cancers and to collaborate with the outstanding genome scientists at UW Medicine.

"I am thrilled at the prospect of working with the world's leading experts in genome sciences, computational biology and those involved in the development of novel platforms for delivering innovative therapies to cancer patients," Holland said. "The highly collaborative, multidisciplinary nature of cancer research at Fred Hutch and UW Medicine provides a solid foundation to build on."

Holland is currently the Emily Tow Jackson Chair in Oncology and the founding director of the Brain Tumor Center at Sloan-Kettering, where he has built one of the nation's most successful brain cancer research and clinical programs. He specializes in the research and treatment of glioma – the most common brain cancer in adults – and metastatic brain tumors. 

Throughout his career Holland has worked at the intersection of multiple disciplines to address the molecular basis of brain tumors and develop new approaches to their treatment. His research focuses on developing mouse models of brain cancer that mimic the behavior of the disease in patients. His work with mouse models has led to clinical trials in glioma patients. He also has developed imaging strategies to follow mouse brain tumors as they develop – a powerful system that is used to test promising new drugs with potential benefit for patients.

Among Holland's discoveries:

  • He was the first to use a system of postnatal gene transfer to study brain cancer formation in mice, providing a model for the development of gliomas and medulloblastomas.
  • His laboratory was the first to demonstrate that stem cells are more sensitive to changes that can lead to cancer, providing clues to cancer development and its ability to evade treatment.
  • He was the first to demonstrate that the activity of a protein called Akt is elevated in human glioblastomas – a finding that provided major insights into the development of this cancer.

Holland received his medical degree from Stanford University and his doctorate in molecular biology from the University of Chicago. His postdoctoral training included work with two Nobel laureates: Paul Berg, Ph.D., a pioneer of recombinant DNA technology at Stanford University; and Harold Varmus, M.D., director of the National Cancer Institute and former director of the National Institutes of Health. Prior to Holland's arrival at Sloan-Kettering in 2001 he conducted brain surgery and basic research at the University of Texas MD Anderson Cancer Center. He is a member of the National Academy of Sciences' prestigious Institute of Medicine.

About Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

About UW Medicine
UW Medicine includes: Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, UW Medical Center, UW Neighborhood Clinics, UW Physicians, UW School of Medicine and Airlift Northwest. UW Medicine has major academic and service affiliations with Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, the Veteran's Affairs Puget Sound Health Care System in Seattle, and the VA Hospital in Boise, Idaho. The UW School of Medicine is the top public institution for receipt of biomedical research funding from the National Institutes of Health (NIH) and second among all institutions for NIH funding, public and private.  UW Medicine's 2,000 full-time faculty and nearly 5,000 clinical faculty across its five-state WWAMI region (Washington, Wyoming, Alaska, Montana and Idaho) include three living Nobel Prize winners (five in its history), 32 members of the National Academy of Sciences, 35 members of the Institute of Medicine, and 13 Howard Hughes Medical Institute Investigators. For more information, visit UW Medicine. Follow us on Twitter – @UWMedicineNews

CONTACTS
Kristen Woodward – Fred Hutch
206-667-5095
[email protected]

Clare LaFond – UW Medicine
206-685-1323
[email protected]

SOURCE Fred Hutchinson Cancer Research Center

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
CenturyLink has announced that application server solutions from GENBAND are now available as part of CenturyLink’s Networx contracts. The General Services Administration (GSA)’s Networx program includes the largest telecommunications contract vehicles ever awarded by the federal government. CenturyLink recently secured an extension through spring 2020 of its offerings available to federal government agencies via GSA’s Networx Universal and Enterprise contracts. GENBAND’s EXPERiUS™ Application...
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...